Codexis, Inc. (0I0X.L)
USD 5.58
(-2.26%)
USD 5.58
(-2.26%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 66.51 Million USD | -19.4% |
| 2022 | 132.27 Million USD | 25.68% |
| 2021 | 105.24 Million USD | 32.82% |
| 2020 | 79.23 Million USD | 21.2% |
| 2019 | 65.37 Million USD | 10.3% |
| 2018 | 59.26 Million USD | 1.03% |
| 2017 | 58.66 Million USD | 23.13% |
| 2016 | 47.64 Million USD | 10.84% |
| 2015 | 42.98 Million USD | -3.81% |
| 2014 | 44.69 Million USD | -23.62% |
| 2013 | 58.51 Million USD | -33.63% |
| 2012 | 88.16 Million USD | -10.03% |
| 2011 | 97.99 Million USD | 13.62% |
| 2010 | 86.24 Million USD | 1.95% |
| 2009 | 84.59 Million USD | 4.1% |
| 2008 | 81.26 Million USD | 46.8% |
| 2007 | 55.35 Million USD | 89.99% |
| 2006 | 29.13 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 25.84 Million USD | 13.09% |
| 2024 Q3 | 25.07 Million USD | -2.99% |
| 2024 Q1 | 22.85 Million USD | 2.94% |
| 2023 FY | 106.61 Million USD | -19.4% |
| 2023 Q4 | 22.2 Million USD | -14.49% |
| 2023 Q2 | 30.69 Million USD | -4.23% |
| 2023 Q3 | 25.96 Million USD | -15.42% |
| 2023 Q1 | 32.05 Million USD | 0.16% |
| 2022 Q4 | 32 Million USD | -9.39% |
| 2022 Q3 | 35.32 Million USD | 18.74% |
| 2022 Q1 | 35.2 Million USD | 25.37% |
| 2022 Q2 | 29.74 Million USD | -15.51% |
| 2022 FY | 132.27 Million USD | 25.68% |
| 2021 Q3 | 28.57 Million USD | 11.52% |
| 2021 Q1 | 22.96 Million USD | 20.28% |
| 2021 Q4 | 28.08 Million USD | -1.72% |
| 2021 FY | 105.24 Million USD | 32.82% |
| 2021 Q2 | 25.62 Million USD | 11.55% |
| 2020 Q4 | 19.09 Million USD | -8.22% |
| 2020 FY | 79.23 Million USD | 21.2% |
| 2020 Q2 | 19.37 Million USD | -2.91% |
| 2020 Q1 | 19.95 Million USD | 23.23% |
| 2020 Q3 | 20.8 Million USD | 7.39% |
| 2019 Q2 | 16.17 Million USD | -1.59% |
| 2019 Q3 | 16.58 Million USD | 2.54% |
| 2019 FY | 65.37 Million USD | 10.3% |
| 2019 Q1 | 16.43 Million USD | 14.75% |
| 2019 Q4 | 16.19 Million USD | -2.33% |
| 2018 Q1 | 14.92 Million USD | -13.65% |
| 2018 Q4 | 14.31 Million USD | -6.17% |
| 2018 FY | 59.26 Million USD | 1.03% |
| 2018 Q3 | 15.26 Million USD | 3.36% |
| 2018 Q2 | 14.76 Million USD | -1.07% |
| 2017 Q1 | 12.44 Million USD | -3.77% |
| 2017 Q3 | 16.04 Million USD | 24.43% |
| 2017 Q2 | 12.89 Million USD | 3.61% |
| 2017 FY | 58.66 Million USD | 23.13% |
| 2017 Q4 | 17.28 Million USD | 7.73% |
| 2016 Q3 | 10.69 Million USD | -7.25% |
| 2016 FY | 47.64 Million USD | 10.84% |
| 2016 Q4 | 12.93 Million USD | 20.91% |
| 2016 Q2 | 11.53 Million USD | -7.66% |
| 2016 Q1 | 12.48 Million USD | 11.08% |
| 2015 FY | 42.98 Million USD | -3.81% |
| 2015 Q2 | 10.46 Million USD | -3.73% |
| 2015 Q1 | 10.87 Million USD | 6.64% |
| 2015 Q3 | 10.4 Million USD | -0.54% |
| 2015 Q4 | 11.24 Million USD | 8.0% |
| 2014 Q1 | 10.94 Million USD | -25.09% |
| 2014 Q2 | 13.35 Million USD | 22.04% |
| 2014 Q3 | 10.19 Million USD | -23.68% |
| 2014 Q4 | 10.19 Million USD | -0.01% |
| 2014 FY | 44.69 Million USD | -23.62% |
| 2013 Q1 | 15.44 Million USD | -13.61% |
| 2013 Q2 | 15.79 Million USD | 2.25% |
| 2013 Q3 | 12.66 Million USD | -19.82% |
| 2013 Q4 | 14.61 Million USD | 15.39% |
| 2013 FY | 58.51 Million USD | -33.63% |
| 2012 Q4 | 17.88 Million USD | -19.1% |
| 2012 FY | 88.16 Million USD | -10.03% |
| 2012 Q1 | 25.74 Million USD | 1.64% |
| 2012 Q3 | 22.1 Million USD | -1.51% |
| 2012 Q2 | 22.43 Million USD | -12.84% |
| 2011 Q1 | 22.76 Million USD | 3.48% |
| 2011 Q2 | 24.24 Million USD | 6.49% |
| 2011 Q3 | 25.65 Million USD | 5.84% |
| 2011 Q4 | 25.32 Million USD | -1.28% |
| 2011 FY | 97.99 Million USD | 13.62% |
| 2010 Q3 | 21.01 Million USD | -2.98% |
| 2010 Q1 | 21.58 Million USD | -10.71% |
| 2010 Q4 | 21.99 Million USD | 4.7% |
| 2010 FY | 86.24 Million USD | 1.95% |
| 2010 Q2 | 21.65 Million USD | 0.34% |
| 2009 FY | 84.59 Million USD | 4.1% |
| 2009 Q1 | 21.19 Million USD | 7.53% |
| 2009 Q4 | 24.17 Million USD | 15.44% |
| 2009 Q3 | 20.93 Million USD | 14.48% |
| 2009 Q2 | 18.29 Million USD | -13.71% |
| 2008 Q4 | 19.71 Million USD | 0.0% |
| 2008 FY | 81.26 Million USD | 46.8% |
| 2008 Q1 | 18.59 Million USD | 0.0% |
| 2007 Q1 | 8.79 Million USD | 0.0% |
| 2007 FY | 55.35 Million USD | 89.99% |
| 2006 FY | 29.13 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 60.508% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 85.077% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 73.89% |
| Organovo Holdings, Inc. | 14.91 Million USD | -345.981% |